Annovis Bio Inc.

NYS: ANVS

GO
/marketstate/country/us

After Hours

 --Real time quotes

Nov 30, 2021, 5:06 p.m.

/zigman2/quotes/216213707/composite

$

24.00

Change

-0.06 -0.25%

Volume

Volume 989

Real time quotes

/zigman2/quotes/216213707/composite

Today's close

$ 24.41

$ 24.06

Change

-0.35 -1.43%

Day low

Day high

$22.57

$24.84

Open

52 week low

52 week high

$5.25

$132.00

Open

Company Description

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic...

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Valuation

Price to Book Ratio

6.89

Enterprise Value to EBITDA

-28.56

Efficiency

Income Per Employee

-2,731,023.00

Liquidity

Current Ratio

14.04

Quick Ratio

14.04

Cash Ratio

13.96

Profitability

Return on Assets

-118.27

Return on Equity

-180.82

Return on Total Capital

-203.02

Return on Invested Capital

-167.00

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Maria-Luisa Maccecchini 69 2008 President, Chief Executive Officer & Director
Mr. Jeffrey B. McGroarty 51 2019 Chief Financial Officer
Ms. Cheng Fang - 2021 Vice President-Research
Mr. Michael B. Hoffman 69 2014 Director
Mr. Reid S. McCarthy 66 2021 Independent Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
10/12/2021 Mark White
Director
5,000   Acquisition at $27.4 per share. 137,000
10/11/2021 Maria-Luisa Maccecchini
PRESIDENT AND CEO; Director
18,000   Acquisition at $27.61 per share. 496,980
10/11/2021 Claudine E. Bruck
Director
181   Acquisition at $27.66 per share. 5,006
08/19/2021 Reid S. McCarthy
Director
500   Acquisition at $37.61 per share. 18,805
02/03/2020 Jeffrey B. McGroarty
Chief Financial Officer
164   Acquisition at $7.17 per share. 1,175
02/03/2020 Jeffrey B. McGroarty
Chief Financial Officer
19,336   Acquisition at $7.15 per share. 138,252
01/31/2020 Michael B. Hoffman
Director
55,884   Derivative/Non-derivative trans. at $4.8 per share. 268,243
01/31/2020 Michael B. Hoffman
Director
1,137,942   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Michael B. Hoffman
Director
158,730   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Maria-Luisa Maccecchini
PRESIDENT AND CEO; Director
762,896   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Maria-Luisa Maccecchini
PRESIDENT AND CEO; Director
7,937   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Robert M. Whelan
Director
11,176   Derivative/Non-derivative trans. at $4.8 per share. 53,644
01/31/2020 Robert M. Whelan
Director
59,524   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Mark White
Director
3,252   Derivative/Non-derivative trans. at $4.8 per share. 15,609
01/31/2020 Mark White
Director
34,643   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Mark White
Director
11,548   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Claudine E. Bruck
Director
1,117   Derivative/Non-derivative trans. at $4.8 per share. 5,361
01/31/2020 Claudine E. Bruck
Director
3,969   Derivative/Non-derivative trans. at $0 per share. 0
01/31/2020 Michael B. Hoffman
Director
33,333   Acquisition at $6 per share. 199,998
01/31/2020 Maria-Luisa Maccecchini
PRESIDENT AND CEO; Director
1,600   Acquisition at $6 per share. 9,600
01/31/2020 Robert M. Whelan
Director
25,000   Acquisition at $6 per share. 150,000
01/31/2020 Mark White
Director
1,734   Acquisition at $6 per share. 10,404
01/31/2020 Jeffrey B. McGroarty
Chief Financial Officer
33,333   Acquisition at $6 per share. 199,998
01/31/2020 Claudine E. Bruck
Director
800   Acquisition at $6 per share. 4,800
/news/latest/company/us/anvs

MarketWatch News on ANVS

  1. Annovis Bio stock price target cut to $70 from $150 at Maxim Group

    6:43 a.m. Oct. 8, 2021

    - Tomi Kilgore

  2. Analyst Raises Price Targets on 3 Smaller Alzheimer's Stocks

    10:50 a.m. July 7, 2021

    - Barron's Online

  3. Annovis Bio stock price target raised to $150 from $45 at Maxim Group

    7:30 a.m. July 7, 2021

    - Tomi Kilgore

  4. Annovis Bio stock price target raised to $45 from $12 at Maxim Group

    6:33 a.m. May 13, 2021

    - Tomi Kilgore

  5. Annovis Bio started at buy with $12 stock price target at Maxim Group

    6:57 a.m. June 18, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/anvs

Other News on ANVS

  1. RKL Wealth Management LLC Buys Tesla Inc, Dimensional U.S. ...

    1:38 p.m. Nov. 16, 2021

    - GuruFocus.com

  2. CHPT, MARA and BLNK among pre market gainers

    8:34 a.m. Nov. 8, 2021

    - Seeking Alpha

  3. 10-Q: ANNOVIS BIO, INC.

    9:57 a.m. Nov. 3, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  4. SESN, BWEN and CETX among mid-day movers

    12:53 p.m. Oct. 14, 2021

    - Seeking Alpha

  5. Annovis Bio up 7% after-hours following CEO, insider buys

    5:28 p.m. Oct. 13, 2021

    - Seeking Alpha

  6. Annovis Bio: An Update

    3:54 p.m. Oct. 6, 2021

    - Seeking Alpha

  7. OCGN, ZIOP and SFT among pre market gainers

    8:18 a.m. Oct. 5, 2021

    - Seeking Alpha

  8. Annovis Bio (ANVS) Investor Presentation - Slideshow

    3:36 p.m. Oct. 1, 2021

    - Seeking Alpha

  9. Loading more headlines...

At a Glance

Annovis Bio, Inc.

1055 Westlakes Drive

Suite 300

Berwyn, Pennsylvania 19312

Phone

1 6107273913

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

N/A

Net Income

$-5.46M

Employees

2.00

/news/pressrelease/company/us/anvs

Press Releases on ANVS

  1. Loading more headlines...
Link to MarketWatch's Slice.